Source:http://linkedlifedata.com/resource/pubmed/id/10446927
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1999-10-28
|
pubmed:abstractText |
We have evaluated, as a vector for gene transfer into human T lymphocytes, a recombinant adenovirus (rAd-MFG-AP) carrying a modified, membrane-exposed, alkaline phosphatase (AP) as reporter gene. CD3+ cells were selected from the buffy coat of healthy donors by the immunomagnetic technique. The positive cell population, comprising 96+/-2% CD3+ cells, was cultured with clinical-grade cytokine(s) for 3-7 days prior to rAd-MFG-AP transduction and the transgene expression was evaluated 48 hr later by indirect immunofluorescence flow cytometry assay with an anti-alkaline phosphatase antibody. The best efficiency of transduction was achieved on incubation of CD3+ cells with IL-2 plus either IL-12 (AP+ cells, 12+/-3%) or IL-7 (AP+ cells, 11+/-3%). To increase further the efficiency of transduction, we have combined LipofectAMINE and rAd-MFG-AP with the aim to enhance the uptake of viral particles into the target cells. The percentage of CD3+ cells transduced by rAd-MFG-AP-LipofectAMINE complex was 24+/-4% (range, 20-35%) after incubation with IL-2 plus IL-7 and 22+/-4% (range, 18-32%) after incubation with II-2 plus IL-12. Forty-eight hours after the incubation with rAd-MFG-AP, the transduced T lymphocytes were subjected to fluorescence-activated cell sorting and fractionated into AP+ and AP- cell subpopulations. The AP+ cell fraction, comprising 96.8% of AP+ cells, was evaluated by FACScan analysis for T lymphocyte surface antigens. The immunophenotyping of the transduced T lymphocytes has shown that there was not a particular subtype of T lymphocytes more susceptible to rAd-MFG-AP transduction. In addition, the transgene expression did not modify T lymphocyte functions, as demonstrated by results obtained by cytotoxicity assay before and after rAd-MFG-AP-LipofectAMINE complex transduction. In conclusion, human T lymphocytes can be efficiently transduced, under clinically applicable conditions, by adenovirus-LipofectAMINE complex after 7 days of culture with IL-2 and IL-12 or IL-7.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alkaline Phosphatase,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Cation Exchange Resins,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-7,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipofectamine,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1043-0342
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1875-84
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10446927-Adenoviridae,
pubmed-meshheading:10446927-Alkaline Phosphatase,
pubmed-meshheading:10446927-Antigens, CD3,
pubmed-meshheading:10446927-Cation Exchange Resins,
pubmed-meshheading:10446927-Cytotoxicity, Immunologic,
pubmed-meshheading:10446927-Flow Cytometry,
pubmed-meshheading:10446927-Gene Transfer Techniques,
pubmed-meshheading:10446927-Genetic Vectors,
pubmed-meshheading:10446927-Humans,
pubmed-meshheading:10446927-Interleukin-2,
pubmed-meshheading:10446927-Interleukin-7,
pubmed-meshheading:10446927-Lipid Metabolism,
pubmed-meshheading:10446927-Lipids,
pubmed-meshheading:10446927-Lymphocyte Activation,
pubmed-meshheading:10446927-Recombinant Proteins,
pubmed-meshheading:10446927-T-Lymphocytes,
pubmed-meshheading:10446927-Transduction, Genetic
|
pubmed:year |
1999
|
pubmed:articleTitle |
Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes.
|
pubmed:affiliation |
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy. dinicola@istitutotumori.mi.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|